Pharmaceuticals, Biotechnology and Life Sciences
Tricida has closed public offering of common stock and full exercise of underwriters’ option to ourchase additional shares
Unprecedented clinical results for DaxibotulinumtoxinA for Injection(DAXI), Revance’s long-acting neuromodulator, were highlighted at the 17thAesthetics & Anti-Aging Medical World Congress in Monte-Carlo
United Therapeutics Corporation Monday said that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event.
Azitra will be presenting results from the joint researchshowing the successful genetic engineering of the common skin bacterium, Staphylococcusepidermidis, to produce high levels of functional LEKTI protein, aprotease inhibitor involved in regulating the rate of skin loss.
SAN FRANCISCO–(BUSINESS WIRE)–SmithRx, a San Francisco based technology company and Pharmacy Benefit Manager (PBM), today released the company’s public comment…
The new treatment can potentially provide benefits superior to other commontherapies greatly improving clinical outcomes for patients being treatedfor lung cancer.
Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended) The…
SAN DIEGO–(BUSINESS WIRE)–Turning Point Therapeutics, Inc., a clinical-stage precision oncology company developing novel drugs that address treatment resistance, announced today…
Novel DNA Manufacturing Platform Seeks to Pioneer New Generation of Faster, More Affordable Cell-based Therapeutics for Patients STONY BROOK, N.Y.–(BUSINESS…
QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing…